结性脊柱炎的遗传风险和克罗恩病的二线治疗需求:孟德尔的随机化研究
Mahmud Omar1, Mohammad Omar2, Yonatan Shneor Patt3
1Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel.
Journal of clinical medicine
|January 8, 2025
概括
对结性脊柱炎 (AS) 的遗传倾向与需要对克罗恩病进行积极治疗的可能性更高有关.
科学领域:
- 免疫遗传学 免疫遗传学
- 胃肠病学 胃肠病学
- 类风湿病学 类风湿病学
背景情况:
- 克罗恩病 (CD) 和化脊柱炎 (AS) 具有共同的炎症途径.
- 调查AS和侵袭性CD治疗需求之间的遗传联系.
研究的目的:
- 为了确定AS的遗传因素是否影响CD的严重程度和治疗要求.
- 探索针对AS和CD共存的个性化医疗方法.
主要方法:
- 使用AS和CD的GWAS数据进行双样本孟德尔随机化 (TSMR).
- 选择全基因组显著的单核酸多态 (SNP) 作为仪器变量.
- 反变量加权 (IVW) 和MR埃格尔分析与灵敏度测试.
主要成果:
- 在AS遗传倾向和二线CD治疗需求增加之间发现了显著的关联.
- IVW (OR=2.16) 和MR Egger (OR=2.71) 分析证实了这一关联.
- 通过敏感性分析验证发现的可靠性,不包括异常SNP.
结论:
- 对AS的遗传因素可能会加速CD的进展,表明需要密集治疗.
- 建议在CD患者中早期查AS,以量身定制治疗策略.
- 突出了个性化医疗在管理这些慢性炎症疾病的潜力.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Genome-wide Association Studies-GWAS
12.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Inflammatory Bowel Disease IV: Pharmacological Management
110
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
110
Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119


